Celcuity Inc (CELC) Stock Analysis
Verdict: HOLD
FDA approval is priced in and de-risked; the story now pivots to commercial execution and 2026 revenue targets totaling $0.39B.
Investment score: 64/100
Analysis as of
Is Celcuity Inc stock worth reviewing? AI model thesis
The model identifies CELC as a high-potential commercial-stage biotech that is currently undergoing a technical correction following its primary catalyst (FDA approval).
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 70/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 95/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
Celcuity Inc opportunities and risks
What speaks for CELC
- Commercial Launch Momentum
What speaks against CELC
- Commercial Execution Lag
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CELC | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.9% |
| CAI | n/a | 5.4x | 40.8x | 68.7% | 3.7% | 2.5% |
| TNGX | n/a | 66.0x | n/a | 97.3% | -188.2% | -3.8% |
| VCYT | 53.7x | 8.8x | 40.3x | 71.3% | 16.2% | 3.3% |
| ACAD | 11.6x | 4.1x | 33.2x | 91.5% | 34.3% | 4.8% |
| VKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.8% |
| Peer median | n/a | 5.4x | 33.2x | 71.3% | 3.7% | 2.5% |
Frequently asked questions about Celcuity Inc (CELC)
Is CELC stock a good investment?
The cached TradeMates AI model rates Celcuity Inc as HOLD with an investment score of 64/100. The model identifies CELC as a high-potential commercial-stage biotech that is currently undergoing a technical correction following its primary catalyst (FDA approval). This is algorithmic model output, not personal investment advice.
Is CELC stock a buy?
The TradeMates model verdict for CELC is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.